# Study to Compare the Pharmacokinetics and Pharmacodynamics of 6 mg RGB-02 to 6 mg Neulasta

> **NCT03146988** · PHASE1 · COMPLETED · sponsor: **Gedeon Richter Plc.** · enrollment: 150 (actual)

## Conditions studied

- Bioequivalence

## Interventions

- **DRUG:** RGB-02 or Neulasta® (pegfilgrastim)

## Key facts

- **NCT ID:** NCT03146988
- **Lead sponsor:** Gedeon Richter Plc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-10
- **Primary completion:** 2017-09-14
- **Final completion:** 2017-10-04
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2017-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03146988

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03146988, "Study to Compare the Pharmacokinetics and Pharmacodynamics of 6 mg RGB-02 to 6 mg Neulasta". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03146988. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*